,title,geo_accession,status,submission_date,last_update_date,type,channel_count,source_name_ch1,organism_ch1,taxid_ch1,characteristics_ch1.0.disease state,characteristics_ch1.1.cell type,characteristics_ch1.2.idh1,characteristics_ch1.3.idh2,characteristics_ch1.4.gender,characteristics_ch1.5.age,characteristics_ch1.6.score,characteristics_ch1.7.risk,characteristics_ch1.8.cebpa,characteristics_ch1.9.karyotype,characteristics_ch1.10.npm1,characteristics_ch1.11.flt3 itd mutation,characteristics_ch1.12.flt3 tkd mutation,characteristics_ch1.13.n-ras mutation,characteristics_ch1.14.k-ras mutation,characteristics_ch1.15.evi1 expression,characteristics_ch1.16.cebpa mutation,molecule_ch1,extract_protocol_ch1,label_ch1,label_protocol_ch1,hyb_protocol,scan_protocol,description,data_processing,platform_id,contact_name,contact_email,contact_laboratory,contact_department,contact_institute,contact_address,contact_city,contact_state,contact_zip/postal_code,contact_country,contact_web_link,supplementary_file,relation,series_id,data_row_count,characteristics_ch1.9.karyotype:,characteristics_ch1.2.gender,characteristics_ch1.3.age,characteristics_ch1.4.score,characteristics_ch1.5.risk,characteristics_ch1.6.cebpa,characteristics_ch1.7.karyotype:,characteristics_ch1.8.npm1,characteristics_ch1.9.flt3 itd mutation,characteristics_ch1.10.flt3 tkd mutation,characteristics_ch1.11.n-ras mutation,characteristics_ch1.12.k-ras mutation,characteristics_ch1.13.evi1 expression,characteristics_ch1.14.cebpa mutation,characteristics_ch1.7.karyotype,characteristics_ch1.0.cell type,characteristics_ch1.1.disease state,treatment_protocol_ch1
GSM158711,AML 2199,GSM158711,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,54 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158711/suppl/GSM158711.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158712,AML 2200,GSM158712,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,38 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158712/suppl/GSM158712.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158713,AML 2201,GSM158713,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,33 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158713/suppl/GSM158713.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158714,AML 2202,GSM158714,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,35 years,FAB M4E,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158714/suppl/GSM158714.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158715,AML 2203,GSM158715,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,37 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158715/suppl/GSM158715.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158716,AML 2204,GSM158716,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,50 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158716/suppl/GSM158716.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158717,AML 2206,GSM158717,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,50 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158717/suppl/GSM158717.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158718,AML 2207,GSM158718,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,30 years,FAB M1,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158718/suppl/GSM158718.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158719,AML 2208,GSM158719,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,48 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158719/suppl/GSM158719.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158720,AML 2209,GSM158720,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,55 years,FAB M4,cytogenetic intermediate,wild type,Other,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158720/suppl/GSM158720.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158721,AML 2210,GSM158721,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,37 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158721/suppl/GSM158721.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158722,AML 2211,GSM158722,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,28 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158722/suppl/GSM158722.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158723,AML 2212,GSM158723,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,60 years,FAB M2,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158723/suppl/GSM158723.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158724,AML 2214,GSM158724,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,25 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158724/suppl/GSM158724.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158725,AML 2215,GSM158725,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,31 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158725/suppl/GSM158725.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158726,AML 2216,GSM158726,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,58 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158726/suppl/GSM158726.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158727,AML 2218,GSM158727,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,40 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158727/suppl/GSM158727.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158728,AML 2219,GSM158728,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,31 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158728/suppl/GSM158728.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158729,AML 2220,GSM158729,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,48 years,FAB M5,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158729/suppl/GSM158729.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158730,AML 2222,GSM158730,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,53 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158730/suppl/GSM158730.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158731,AML 2223,GSM158731,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M2,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158731/suppl/GSM158731.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158732,AML 2224,GSM158732,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,45 years,FAB M6,cytogenetic intermediate,wild type,,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158732/suppl/GSM158732.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158733,AML 2225,GSM158733,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,47 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158733/suppl/GSM158733.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158734,AML 2226,GSM158734,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,33 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158734/suppl/GSM158734.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158735,AML 2227,GSM158735,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,34 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158735/suppl/GSM158735.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158736,AML 2228,GSM158736,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,41 years,FAB M4,cytogenetic poor,wild type,NN,Neg,Neg,Neg,Pos,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158736/suppl/GSM158736.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158737,AML 2229,GSM158737,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,43 years,FAB M4,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158737/suppl/GSM158737.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158738,AML 2230,GSM158738,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,37 years,FAB M2,cytogenetic intermediate,double mutant,NN,Neg,Pos,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158738/suppl/GSM158738.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158739,AML 2231,GSM158739,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158739/suppl/GSM158739.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158740,AML 2233,GSM158740,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,59 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158740/suppl/GSM158740.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158741,AML 2234,GSM158741,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,37 years,FAB M2,cytogenetic intermediate,double mutant,Other,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158741/suppl/GSM158741.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158742,AML 2235,GSM158742,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158742/suppl/GSM158742.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158743,AML 2236,GSM158743,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,36 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158743/suppl/GSM158743.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158744,AML 2237,GSM158744,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,57 years,FAB M1,cytogenetic poor,single mutant,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158744/suppl/GSM158744.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158745,AML 2238,GSM158745,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,21 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158745/suppl/GSM158745.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158746,AML 2239,GSM158746,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,48 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158746/suppl/GSM158746.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158747,AML 2240,GSM158747,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,48 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158747/suppl/GSM158747.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158748,AML 2241,GSM158748,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,53 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158748/suppl/GSM158748.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158749,AML 2242,GSM158749,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M1,cytogenetic intermediate,double mutant,-9q,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158749/suppl/GSM158749.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158750,AML 2243,GSM158750,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,26 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158750/suppl/GSM158750.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158751,AML 2244,GSM158751,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,FAB M5,cytogenetic poor,wild type,+8,Pos,Neg,Neg,Neg,Pos,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158751/suppl/GSM158751.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158752,AML 2245,GSM158752,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,47 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158752/suppl/GSM158752.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158753,AML 2246,GSM158753,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,33 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158753/suppl/GSM158753.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158754,AML 2247,GSM158754,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,47 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158754/suppl/GSM158754.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158755,AML 2248,GSM158755,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158755/suppl/GSM158755.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158756,AML 2249,GSM158756,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,29 years,FAB M5,cytogenetic good,wild type,-5/7(q),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158756/suppl/GSM158756.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158757,AML 2250,GSM158757,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,18 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158757/suppl/GSM158757.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158758,AML 2251,GSM158758,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,55 years,FAB M2,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158758/suppl/GSM158758.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158759,AML 2205,GSM158759,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,33 years,FAB M2,cytogenetic poor,wild type,t(6;9),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158759/suppl/GSM158759.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158760,AML 2217,GSM158760,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,53 years,FAB M5,cytogenetic intermediate,wild type,+8,Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158760/suppl/GSM158760.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158761,AML 2327,GSM158761,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M2,cytogenetic poor,wild type,-5/7(q),Neg,Pos,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158761/suppl/GSM158761.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158762,AML 1174,GSM158762,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158762/suppl/GSM158762.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158763,AML 1188,GSM158763,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,33 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158763/suppl/GSM158763.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158764,AML 1197,GSM158764,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,51 years,FAB M0,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158764/suppl/GSM158764.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158765,AML 1299,GSM158765,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,32 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158765/suppl/GSM158765.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158766,AML 1316,GSM158766,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,19 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Pos,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158766/suppl/GSM158766.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158767,AML 1432,GSM158767,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,53 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158767/suppl/GSM158767.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158768,AML 1551,GSM158768,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158768/suppl/GSM158768.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158769,AML 1595,GSM158769,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158769/suppl/GSM158769.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158770,AML 1747,GSM158770,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,59 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158770/suppl/GSM158770.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158771,AML 1766,GSM158771,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,52 years,FAB unknown,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158771/suppl/GSM158771.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158772,AML 2169,GSM158772,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,60 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Pos,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158772/suppl/GSM158772.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158773,AML 2170,GSM158773,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,54 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158773/suppl/GSM158773.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158774,AML 2171,GSM158774,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,40 years,FAB M4,cytogenetic intermediate,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158774/suppl/GSM158774.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158775,AML 2172,GSM158775,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,18 years,FAB M4,cytogenetic good,wild type,NN,Neg,Neg,Pos,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158775/suppl/GSM158775.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158776,AML 2173,GSM158776,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,55 years,FAB M1,cytogenetic intermediate,wild type,Other,Pos,Pos,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158776/suppl/GSM158776.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158777,AML 2174,GSM158777,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,45 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158777/suppl/GSM158777.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158778,AML 2175,GSM158778,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,57 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158778/suppl/GSM158778.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158779,AML 2176,GSM158779,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,41 years,FAB M4,cytogenetic intermediate,single mutant,NN,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158779/suppl/GSM158779.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158780,AML 2177,GSM158780,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,18 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158780/suppl/GSM158780.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158781,AML 2178,GSM158781,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,46 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158781/suppl/GSM158781.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158782,AML 2179,GSM158782,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,53 years,FAB M4,cytogenetic good,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158782/suppl/GSM158782.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158783,AML 2181,GSM158783,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,39 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158783/suppl/GSM158783.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158784,AML 2182,GSM158784,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,20 years,FAB M5,cytogenetic intermediate,wild type,+8,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158784/suppl/GSM158784.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158785,AML 2183,GSM158785,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,52 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158785/suppl/GSM158785.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158786,AML 2184,GSM158786,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,47 years,FAB M5,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158786/suppl/GSM158786.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158787,AML 2185,GSM158787,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,50 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158787/suppl/GSM158787.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158788,AML 2186,GSM158788,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,39 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158788/suppl/GSM158788.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158789,AML 2187,GSM158789,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,50 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158789/suppl/GSM158789.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158790,AML 2188,GSM158790,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,51 years,FAB M2,cytogenetic intermediate,single mutant,+8,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158790/suppl/GSM158790.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158791,AML 2189,GSM158791,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,53 years,FAB M4E,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158791/suppl/GSM158791.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158792,AML 2190,GSM158792,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,15 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Pos,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158792/suppl/GSM158792.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158793,AML 2191,GSM158793,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,45 years,FAB Mx,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Pos,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158793/suppl/GSM158793.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158794,AML 2192,GSM158794,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,45 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158794/suppl/GSM158794.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158795,AML 2193,GSM158795,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,50 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158795/suppl/GSM158795.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158796,AML 2194,GSM158796,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,20 years,FAB M4,cytogenetic intermediate,single mutant,NN,Neg,Pos,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158796/suppl/GSM158796.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158797,AML 2195,GSM158797,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158797/suppl/GSM158797.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158798,AML 2196,GSM158798,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,19 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158798/suppl/GSM158798.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158799,AML 2197,GSM158799,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,24 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158799/suppl/GSM158799.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158800,AML 2198,GSM158800,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158800/suppl/GSM158800.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158801,AML 2252,GSM158801,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,27 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158801/suppl/GSM158801.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158802,AML 2253,GSM158802,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,43 years,FAB M2,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158802/suppl/GSM158802.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158803,AML 2254,GSM158803,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,23 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158803/suppl/GSM158803.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158804,AML 2255,GSM158804,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,44 years,FAB M1,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Pos,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158804/suppl/GSM158804.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158805,AML 2256,GSM158805,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158805/suppl/GSM158805.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158806,AML 2257,GSM158806,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,40 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158806/suppl/GSM158806.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158807,AML 2259,GSM158807,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,18 years,FAB M4,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158807/suppl/GSM158807.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158808,AML 2260,GSM158808,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,18 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158808/suppl/GSM158808.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158809,AML 2261,GSM158809,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,37 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158809/suppl/GSM158809.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158810,AML 2262,GSM158810,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,39 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158810/suppl/GSM158810.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158811,AML 2263,GSM158811,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,31 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158811/suppl/GSM158811.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158812,AML 2265,GSM158812,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,21 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158812/suppl/GSM158812.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158813,AML 2266,GSM158813,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,58 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158813/suppl/GSM158813.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158814,AML 2267,GSM158814,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,29 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158814/suppl/GSM158814.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158815,AML 2268,GSM158815,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,56 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158815/suppl/GSM158815.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158816,AML 2270,GSM158816,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,41 years,FAB M1,cytogenetic intermediate,wild type,+8,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158816/suppl/GSM158816.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158817,AML 2271,GSM158817,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158817/suppl/GSM158817.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158818,AML 2272,GSM158818,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,35 years,FAB M5,cytogenetic poor,wild type,+8,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158818/suppl/GSM158818.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158819,AML 2273,GSM158819,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,16 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158819/suppl/GSM158819.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158820,AML 2274,GSM158820,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,46 years,FAB M4,cytogenetic good,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158820/suppl/GSM158820.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158821,AML 2275,GSM158821,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,46 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158821/suppl/GSM158821.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158822,AML 2276,GSM158822,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M0,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158822/suppl/GSM158822.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158823,AML 2278,GSM158823,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,45 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158823/suppl/GSM158823.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158824,AML 2281,GSM158824,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,20 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158824/suppl/GSM158824.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158825,AML 2282,GSM158825,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,44 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158825/suppl/GSM158825.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158826,AML 2283,GSM158826,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,57 years,FAB M4,cytogenetic poor,wild type,+8,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158826/suppl/GSM158826.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158827,AML 2284,GSM158827,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,32 years,FAB M6,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158827/suppl/GSM158827.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158828,AML 2285,GSM158828,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,17 years,FAB M5,cytogenetic poor,wild type,Other,Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158828/suppl/GSM158828.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158829,AML 2286,GSM158829,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158829/suppl/GSM158829.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158830,AML 2287,GSM158830,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,16 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158830/suppl/GSM158830.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158831,AML 2288,GSM158831,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,31 years,FAB M4,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158831/suppl/GSM158831.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158832,AML 2289,GSM158832,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,50 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Pos,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158832/suppl/GSM158832.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158833,AML 322,GSM158833,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M3,cytogenetic good,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158833/suppl/GSM158833.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158834,AML 2279,GSM158834,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M4,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158834/suppl/GSM158834.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158835,AML 2280,GSM158835,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,49 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158835/suppl/GSM158835.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158836,AML 2290,GSM158836,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,41 years,FAB M2,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158836/suppl/GSM158836.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158837,AML 2291,GSM158837,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M5,cytogenetic intermediate,wild type,+8,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158837/suppl/GSM158837.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158838,AML 2292,GSM158838,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,56 years,FAB M5,cytogenetic intermediate,wild type,+8,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158838/suppl/GSM158838.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158839,AML 2293,GSM158839,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,57 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158839/suppl/GSM158839.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158840,AML 2296,GSM158840,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,38 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158840/suppl/GSM158840.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158841,AML 2297,GSM158841,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,37 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158841/suppl/GSM158841.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158842,AML 2299,GSM158842,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,39 years,FAB M2,cytogenetic intermediate,wild type,Other,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158842/suppl/GSM158842.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158843,AML 2300,GSM158843,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,56 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158843/suppl/GSM158843.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158844,AML 2301,GSM158844,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,24 years,FAB M1,cytogenetic intermediate,wild type,failure,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158844/suppl/GSM158844.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158845,AML 2302,GSM158845,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,34 years,FAB M1,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158845/suppl/GSM158845.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158846,AML 2304,GSM158846,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M0,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158846/suppl/GSM158846.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158847,AML 2305,GSM158847,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,27 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158847/suppl/GSM158847.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158848,AML 2306,GSM158848,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158848/suppl/GSM158848.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158849,AML 2307,GSM158849,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,48 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158849/suppl/GSM158849.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158850,AML 2326,GSM158850,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,30 years,FAB M2,cytogenetic poor,wild type,t(9;22),Pos,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158850/suppl/GSM158850.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158851,AML 2466,GSM158851,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,39 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158851/suppl/GSM158851.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158852,AML 2467,GSM158852,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,44 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158852/suppl/GSM158852.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158853,AML 2468,GSM158853,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,34 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158853/suppl/GSM158853.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158854,AML 2480,GSM158854,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,34 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158854/suppl/GSM158854.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158855,AML 2490,GSM158855,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,56 years,FAB M6,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158855/suppl/GSM158855.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158856,AML 2497,GSM158856,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,20 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158856/suppl/GSM158856.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158857,AML 2498,GSM158857,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,59 years,FAB M4,cytogenetic poor,wild type,t(6;9),Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158857/suppl/GSM158857.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158858,AML 2507,GSM158858,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,48 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158858/suppl/GSM158858.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158859,AML 2509,GSM158859,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158859/suppl/GSM158859.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158860,AML 2510,GSM158860,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,26 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158860/suppl/GSM158860.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158861,AML 2511,GSM158861,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158861/suppl/GSM158861.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158862,AML 2514,GSM158862,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,34 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158862/suppl/GSM158862.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158863,AML 2516,GSM158863,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,51 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158863/suppl/GSM158863.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158864,AML 2524,GSM158864,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158864/suppl/GSM158864.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158865,AML 2525,GSM158865,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,53 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,NULL,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158865/suppl/GSM158865.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158866,AML 2534,GSM158866,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,58 years,FAB M2,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158866/suppl/GSM158866.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158867,AML 2535,GSM158867,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,38 years,FAB M5,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158867/suppl/GSM158867.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158868,AML 2541,GSM158868,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158868/suppl/GSM158868.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158869,AML 2542,GSM158869,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,20 years,FAB M4,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Pos,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158869/suppl/GSM158869.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158870,AML 2543,GSM158870,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,52 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158870/suppl/GSM158870.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158871,AML 2544,GSM158871,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,37 years,FAB M2,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158871/suppl/GSM158871.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158872,AML 2545,GSM158872,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,24 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158872/suppl/GSM158872.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158873,AML 2549,GSM158873,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,26 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158873/suppl/GSM158873.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158874,AML 2550,GSM158874,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,55 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158874/suppl/GSM158874.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158875,AML 2551,GSM158875,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,23 years,FAB M5,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158875/suppl/GSM158875.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158876,AML 2644,GSM158876,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,59 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158876/suppl/GSM158876.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158877,AML 2647,GSM158877,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,22 years,FAB M4E,cytogenetic good,wild type,idt(16),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158877/suppl/GSM158877.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158878,AML 2658,GSM158878,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,33 years,FAB M4,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158878/suppl/GSM158878.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158879,AML 2664,GSM158879,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,33 years,FAB M0,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Pos,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158879/suppl/GSM158879.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158880,AML 2665,GSM158880,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,45 years,FAB M5,cytogenetic poor,wild type,t(6;9),Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158880/suppl/GSM158880.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158881,AML 2666,GSM158881,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,FAB M5,unknown,wild type,failure,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158881/suppl/GSM158881.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158882,AML 2668,GSM158882,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,41 years,FAB M0,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158882/suppl/GSM158882.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158883,AML 2669,GSM158883,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,45 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158883/suppl/GSM158883.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158884,AML 2670,GSM158884,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,47 years,FAB M5,cytogenetic poor,wild type,t(6;9),Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158884/suppl/GSM158884.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158885,AML 2671,GSM158885,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,38 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158885/suppl/GSM158885.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158886,AML 2672,GSM158886,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,47 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158886/suppl/GSM158886.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158887,AML 2676,GSM158887,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,47 years,FAB M2,unknown,wild type,failure,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158887/suppl/GSM158887.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158888,AML 2678,GSM158888,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,15 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158888/suppl/GSM158888.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158889,AML 2679,GSM158889,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,39 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158889/suppl/GSM158889.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158890,AML 2680,GSM158890,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,32 years,FAB M2,cytogenetic good,wild type,t(15;17),Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158890/suppl/GSM158890.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158891,AML 2682,GSM158891,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M4,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158891/suppl/GSM158891.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158892,AML 2683,GSM158892,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158892/suppl/GSM158892.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158893,AML 2685,GSM158893,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,42 years,FAB M4,cytogenetic intermediate,wild type,-9q,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158893/suppl/GSM158893.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158894,AML 2686,GSM158894,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,31 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158894/suppl/GSM158894.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158895,AML 2687,GSM158895,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,53 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158895/suppl/GSM158895.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158896,AML 2689,GSM158896,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,53 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158896/suppl/GSM158896.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158897,AML 2690,GSM158897,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,16 years,FAB M2,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158897/suppl/GSM158897.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158898,AML 2692,GSM158898,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,42 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158898/suppl/GSM158898.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158899,AML 2695,GSM158899,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,37 years,FAB M1,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158899/suppl/GSM158899.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158900,AML 2696,GSM158900,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,46 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158900/suppl/GSM158900.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158901,AML 2747,GSM158901,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,22 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158901/suppl/GSM158901.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158902,AML 2748,GSM158902,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,47 years,FAB M4,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158902/suppl/GSM158902.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158903,AML 2749,GSM158903,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,38 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158903/suppl/GSM158903.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158904,AML 2750,GSM158904,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,40 years,FAB M2,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158904/suppl/GSM158904.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158905,AML 2751,GSM158905,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,31 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Pos,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158905/suppl/GSM158905.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158906,AML 2752,GSM158906,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,16 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158906/suppl/GSM158906.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158907,AML 2753,GSM158907,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,34 years,FAB M1,cytogenetic intermediate,double mutant,-9q,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158907/suppl/GSM158907.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158908,AML 2754,GSM158908,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,28 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158908/suppl/GSM158908.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158909,AML 2756,GSM158909,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,37 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158909/suppl/GSM158909.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158910,AML 2757,GSM158910,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,52 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158910/suppl/GSM158910.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158911,AML 2762,GSM158911,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,23 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158911/suppl/GSM158911.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158912,AML 2764,GSM158912,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,21 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158912/suppl/GSM158912.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158913,AML 2765,GSM158913,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,33 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158913/suppl/GSM158913.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158914,AML 2766,GSM158914,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,42 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158914/suppl/GSM158914.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158915,AML 2767,GSM158915,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,36 years,FAB M1,unknown,wild type,failure,Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158915/suppl/GSM158915.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158916,AML 2769,GSM158916,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,55 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158916/suppl/GSM158916.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158917,AML 2771,GSM158917,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,52 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158917/suppl/GSM158917.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158918,AML 3115,GSM158918,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,57 years,FAB M5,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158918/suppl/GSM158918.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158919,AML 3277,GSM158919,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,28 years,FAB M1,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158919/suppl/GSM158919.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158920,AML 3278,GSM158920,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,52 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158920/suppl/GSM158920.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158921,AML 3279,GSM158921,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,22 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158921/suppl/GSM158921.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158922,AML 3285,GSM158922,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,26 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158922/suppl/GSM158922.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158923,AML 3286,GSM158923,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,55 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158923/suppl/GSM158923.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158924,AML 3289,GSM158924,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,46 years,FAB M2,cytogenetic poor,wild type,11q23,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158924/suppl/GSM158924.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158925,AML 3292,GSM158925,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,41 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158925/suppl/GSM158925.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158926,AML 3293,GSM158926,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,36 years,FAB M3,cytogenetic intermediate,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158926/suppl/GSM158926.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158927,AML 3295,GSM158927,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,42 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158927/suppl/GSM158927.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158928,AML 3301,GSM158928,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,56 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Pos,Pos,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158928/suppl/GSM158928.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158929,AML 3304,GSM158929,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,58 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158929/suppl/GSM158929.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158930,AML 3308,GSM158930,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,32 years,FAB M1,cytogenetic poor,wild type,t(9;22),Neg,Neg,Pos,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158930/suppl/GSM158930.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158931,AML 3309,GSM158931,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,32 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Pos,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158931/suppl/GSM158931.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158932,AML 3311,GSM158932,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158932/suppl/GSM158932.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158933,AML 3312,GSM158933,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,19 years,FAB M2,cytogenetic intermediate,wild type,+8,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158933/suppl/GSM158933.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158934,AML 3313,GSM158934,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M0,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158934/suppl/GSM158934.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158935,AML 3314,GSM158935,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,31 years,FAB unknown,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158935/suppl/GSM158935.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158936,AML 3315,GSM158936,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,RAEB-t,cytogenetic poor,wild type,MDS -7(q),Neg,Neg,Neg,Pos,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158936/suppl/GSM158936.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158937,AML 3316,GSM158937,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M5,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158937/suppl/GSM158937.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158938,AML 3317,GSM158938,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,25 years,FAB M5,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158938/suppl/GSM158938.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158939,AML 3318,GSM158939,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,,,,,,,,,,,,,,,,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158939/suppl/GSM158939.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,male,53 years,FAB M2,cytogenetic poor,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,Neg,,,,
GSM158940,AML 3319,GSM158940,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158940/suppl/GSM158940.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158941,AML 3320,GSM158941,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158941/suppl/GSM158941.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158942,AML 3321,GSM158942,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,36 years,FAB M5,cytogenetic intermediate,wild type,+8,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158942/suppl/GSM158942.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158943,AML 3322,GSM158943,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,34 years,FAB M5,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158943/suppl/GSM158943.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158944,AML 3323,GSM158944,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,37 years,FAB M4,cytogenetic intermediate,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158944/suppl/GSM158944.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158945,AML 3324,GSM158945,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,26 years,FAB M5,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158945/suppl/GSM158945.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158946,AML 3325,GSM158946,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,41 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158946/suppl/GSM158946.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158947,AML 3326,GSM158947,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,60 years,FAB M2,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158947/suppl/GSM158947.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158948,AML 3327,GSM158948,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,Pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158948/suppl/GSM158948.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158949,AML 3328,GSM158949,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,41 years,FAB M5,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Neg,Pos,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158949/suppl/GSM158949.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158950,AML 3334,GSM158950,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,RAEB-t,cytogenetic intermediate,wild type,Other,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158950/suppl/GSM158950.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158951,AML 3481,GSM158951,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,46 years,RAEB,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158951/suppl/GSM158951.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158952,AML 3482,GSM158952,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M5,cytogenetic intermediate,wild type,,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158952/suppl/GSM158952.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158953,AML 3483,GSM158953,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,45 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158953/suppl/GSM158953.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158954,AML 3484,GSM158954,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,60 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158954/suppl/GSM158954.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158955,AML 2688,GSM158955,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,40 years,FAB unknown,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158955/suppl/GSM158955.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158956,AML 2694,GSM158956,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,45 years,FAB M5,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158956/suppl/GSM158956.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158957,AML 3310,GSM158957,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,55 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,Neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158957/suppl/GSM158957.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158958,AML 5286,GSM158958,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,57 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158958/suppl/GSM158958.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158959,AML 5365,GSM158959,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,42 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158959/suppl/GSM158959.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158960,AML 6237,GSM158960,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158960/suppl/GSM158960.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158961,AML 6239,GSM158961,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,42 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158961/suppl/GSM158961.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158962,AML 6246,GSM158962,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,25 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158962/suppl/GSM158962.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158963,AML 6247,GSM158963,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,60 years,FAB M2,cytogenetic intermediate,single mutant,NN,Neg,Neg,Neg,Pos,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158963/suppl/GSM158963.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158964,AML 6358,GSM158964,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,45 years,FAB M2,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158964/suppl/GSM158964.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158965,AML 6376,GSM158965,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,36 years,FAB M1,cytogenetic intermediate,double mutant,-9q,Neg,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158965/suppl/GSM158965.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158966,AML 6464,GSM158966,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,25 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158966/suppl/GSM158966.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158967,AML 6465,GSM158967,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M1,cytogenetic intermediate,wild type,Other,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158967/suppl/GSM158967.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158968,AML 6715,GSM158968,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,39 years,FAB M4E,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158968/suppl/GSM158968.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158969,AML 6717,GSM158969,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,58 years,FAB M5,cytogenetic good,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158969/suppl/GSM158969.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158970,AML 6719,GSM158970,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,33 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158970/suppl/GSM158970.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158971,AML 6720,GSM158971,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,38 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158971/suppl/GSM158971.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158972,AML 6721,GSM158972,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,39 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158972/suppl/GSM158972.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158973,AML 6723,GSM158973,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,32 years,FAB M5,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158973/suppl/GSM158973.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158974,AML 6724,GSM158974,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,26 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158974/suppl/GSM158974.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158975,AML 6730,GSM158975,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M3,cytogenetic good,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158975/suppl/GSM158975.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158976,AML 6732,GSM158976,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,38 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158976/suppl/GSM158976.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158977,AML 6734,GSM158977,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158977/suppl/GSM158977.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158978,AML 6735,GSM158978,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,55 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158978/suppl/GSM158978.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158979,AML 6880,GSM158979,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,48 years,FAB M2,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158979/suppl/GSM158979.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158980,AML 6881,GSM158980,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,37 years,FAB M4,cytogenetic good,wild type,failure,Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158980/suppl/GSM158980.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158981,AML 6882,GSM158981,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,37 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158981/suppl/GSM158981.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158982,AML 7081,GSM158982,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,43 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158982/suppl/GSM158982.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158983,AML 7082,GSM158983,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,29 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158983/suppl/GSM158983.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158984,AML 7114,GSM158984,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,54 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158984/suppl/GSM158984.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158985,AML 7115,GSM158985,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,39 years,FAB M4,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158985/suppl/GSM158985.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158986,AML 7124,GSM158986,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158986/suppl/GSM158986.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158987,AML 7125,GSM158987,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,48 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158987/suppl/GSM158987.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158988,AML 7127,GSM158988,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,44 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158988/suppl/GSM158988.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158989,AML 7128,GSM158989,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M5,cytogenetic intermediate,wild type,Other,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158989/suppl/GSM158989.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158990,AML 7131,GSM158990,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,55 years,FAB M1,unknown,wild type,failure,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158990/suppl/GSM158990.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158991,AML 7134,GSM158991,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,FAB M3,cytogenetic good,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158991/suppl/GSM158991.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158992,AML 7137,GSM158992,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,58 years,FAB M5,cytogenetic intermediate,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158992/suppl/GSM158992.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158993,AML 7139,GSM158993,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,53 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158993/suppl/GSM158993.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158994,AML 7142,GSM158994,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M2,cytogenetic poor,double mutant,,Neg,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158994/suppl/GSM158994.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158995,AML 7143,GSM158995,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,27 years,FAB unknown,cytogenetic intermediate,wild type,NN,Neg,Pos,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158995/suppl/GSM158995.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158996,AML 7145,GSM158996,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,50 years,FAB M2,unknown,wild type,failure,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158996/suppl/GSM158996.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158997,AML 7147,GSM158997,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,59 years,FAB M1,unknown,wild type,failure,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158997/suppl/GSM158997.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158998,AML 7149,GSM158998,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,37 years,FAB M5,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Pos,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158998/suppl/GSM158998.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM158999,AML 7150,GSM158999,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,20 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158999/suppl/GSM158999.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159000,AML 7151,GSM159000,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,32 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159000/suppl/GSM159000.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159001,AML 7153,GSM159001,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,22 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159001/suppl/GSM159001.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159002,AML 7154,GSM159002,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,48 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159002/suppl/GSM159002.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159003,AML 7163,GSM159003,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,54 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159003/suppl/GSM159003.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159004,AML 7172,GSM159004,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,55 years,FAB M5,cytogenetic intermediate,wild type,,Pos,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159004/suppl/GSM159004.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159005,AML 7173,GSM159005,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,46 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159005/suppl/GSM159005.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159006,AML 7174,GSM159006,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,26 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159006/suppl/GSM159006.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159007,AML 7177,GSM159007,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,RAEB-t,cytogenetic poor,wild type,MDS -7(q),Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159007/suppl/GSM159007.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159008,AML 7178,GSM159008,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,28 years,FAB M5,unknown,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159008/suppl/GSM159008.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159009,AML 7183,GSM159009,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,51 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159009/suppl/GSM159009.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159010,AML 7185,GSM159010,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,39 years,FAB M2,cytogenetic intermediate,single mutant,NN,Neg,Pos,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159010/suppl/GSM159010.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159011,AML 7276,GSM159011,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,59 years,FAB M4,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159011/suppl/GSM159011.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159012,AML 7277,GSM159012,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,31 years,FAB M4E,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159012/suppl/GSM159012.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159013,AML 7301,GSM159013,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,35 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159013/suppl/GSM159013.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159014,AML 7302,GSM159014,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,50 years,FAB M1,cytogenetic intermediate,single mutant,,Pos,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159014/suppl/GSM159014.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159015,AML 7303,GSM159015,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,38 years,RAEB-t,cytogenetic intermediate,wild type,MDS -Y,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159015/suppl/GSM159015.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159016,AML 7304,GSM159016,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,60 years,FAB M2,cytogenetic poor,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159016/suppl/GSM159016.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159017,AML 7305,GSM159017,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,24 years,FAB M5,cytogenetic intermediate,wild type,,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159017/suppl/GSM159017.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159018,AML 7306,GSM159018,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,FAB M5,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159018/suppl/GSM159018.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159019,AML 7307,GSM159019,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,39 years,FAB M1,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159019/suppl/GSM159019.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159020,AML 7308,GSM159020,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,58 years,FAB M0,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159020/suppl/GSM159020.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159021,AML 7309,GSM159021,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,60 years,RAEB-t,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159021/suppl/GSM159021.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159022,AML 7310,GSM159022,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159022/suppl/GSM159022.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159023,AML 7311,GSM159023,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,53 years,RAEB-t,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159023/suppl/GSM159023.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159024,AML 7313,GSM159024,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M0,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159024/suppl/GSM159024.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159025,AML 7314,GSM159025,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,41 years,FAB M5,cytogenetic intermediate,wild type,,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159025/suppl/GSM159025.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159026,AML 7315,GSM159026,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,45 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159026/suppl/GSM159026.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159027,AML 7316,GSM159027,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,43 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159027/suppl/GSM159027.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159028,AML 7317,GSM159028,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,37 years,RAEB-t,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159028/suppl/GSM159028.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159029,AML 7318,GSM159029,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,60 years,FAB unknown,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159029/suppl/GSM159029.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159030,AML 7319,GSM159030,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,60 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159030/suppl/GSM159030.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159031,AML 7402,GSM159031,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,22 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159031/suppl/GSM159031.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159032,AML 7403,GSM159032,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,46 years,FAB M4,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159032/suppl/GSM159032.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159033,AML 7405,GSM159033,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,47 years,FAB M4,cytogenetic poor,wild type,Other,Neg,Pos,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159033/suppl/GSM159033.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159034,AML 7406,GSM159034,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,25 years,FAB M1,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159034/suppl/GSM159034.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159035,AML 7407,GSM159035,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,38 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159035/suppl/GSM159035.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159036,AML 5282,GSM159036,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159036/suppl/GSM159036.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159037,AML 5283,GSM159037,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,35 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159037/suppl/GSM159037.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159038,AML 5284,GSM159038,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,41 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159038/suppl/GSM159038.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159039,AML 5285,GSM159039,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,59 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159039/suppl/GSM159039.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159040,AML 5356,GSM159040,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,40 years,FAB unknown,cytogenetic poor,wild type,t(6;9),Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159040/suppl/GSM159040.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159041,AML 4333,GSM159041,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,31 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159041/suppl/GSM159041.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159042,AML 4334,GSM159042,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M4,cytogenetic intermediate,wild type,,Pos,Neg,Pos,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159042/suppl/GSM159042.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159043,AML 4335,GSM159043,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,44 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159043/suppl/GSM159043.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159044,AML 4336,GSM159044,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,30 years,RAEB-t,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159044/suppl/GSM159044.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159045,AML 4337,GSM159045,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,56 years,FAB M0,cytogenetic poor,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159045/suppl/GSM159045.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159046,AML 4338,GSM159046,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,50 years,FAB M0,cytogenetic intermediate,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159046/suppl/GSM159046.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159047,AML 4339,GSM159047,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,20 years,RAEB,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159047/suppl/GSM159047.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159048,AML 4340,GSM159048,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,39 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159048/suppl/GSM159048.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159049,AML 4341,GSM159049,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,53 years,RAEB-t,cytogenetic intermediate,single mutant,NN,Pos,Pos,Pos,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159049/suppl/GSM159049.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159050,AML 5357,GSM159050,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,43 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159050/suppl/GSM159050.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159051,AML 5358,GSM159051,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,40 years,FAB M5,cytogenetic poor,wild type,11q23,Neg,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159051/suppl/GSM159051.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159052,AML 5359,GSM159052,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,53 years,FAB M2,cytogenetic poor,wild type,t(6;9),Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159052/suppl/GSM159052.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159053,AML 5362,GSM159053,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,53 years,FAB M2,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Pos,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159053/suppl/GSM159053.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159054,AML 5363,GSM159054,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,55 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159054/suppl/GSM159054.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159055,AML 5364,GSM159055,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,60 years,FAB M2,cytogenetic intermediate,double mutant,NN,Neg,Neg,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159055/suppl/GSM159055.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159056,AML 6236,GSM159056,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,59 years,FAB M2,cytogenetic poor,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159056/suppl/GSM159056.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159057,AML 6360,GSM159057,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,30 years,FAB M2,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159057/suppl/GSM159057.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159058,AML 6362,GSM159058,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,29 years,FAB M1,cytogenetic intermediate,single mutant,NN,Pos,Pos,Neg,Neg,Neg,Neg,nd,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159058/suppl/GSM159058.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159059,AML 6363,GSM159059,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,23 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Pos?,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159059/suppl/GSM159059.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159060,AML 6364,GSM159060,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M5,cytogenetic poor,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159060/suppl/GSM159060.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159061,AML 6365,GSM159061,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159061/suppl/GSM159061.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159062,AML 6366,GSM159062,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,57 years,FAB M2,cytogenetic poor,wild type,Complex,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159062/suppl/GSM159062.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159063,AML 6367,GSM159063,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,48 years,FAB M1,cytogenetic poor,wild type,abn(3q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159063/suppl/GSM159063.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159064,AML 6368,GSM159064,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,49 years,FAB M5,cytogenetic intermediate,wild type,,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159064/suppl/GSM159064.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159065,AML 6369,GSM159065,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,53 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159065/suppl/GSM159065.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159066,AML 6370,GSM159066,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,57 years,FAB M1,cytogenetic intermediate,wild type,-9q,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159066/suppl/GSM159066.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159067,AML 6371,GSM159067,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,43 years,FAB M2,cytogenetic intermediate,wild type,,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159067/suppl/GSM159067.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159068,AML 6372,GSM159068,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,41 years,FAB M1,cytogenetic good,wild type,t(8;21),Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159068/suppl/GSM159068.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159069,AML 6373,GSM159069,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,RAEB-t,cytogenetic poor,wild type,MDS complex,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159069/suppl/GSM159069.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159070,AML 6374,GSM159070,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,55 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159070/suppl/GSM159070.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159071,AML 6375,GSM159071,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,58 years,FAB unknown,cytogenetic poor,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159071/suppl/GSM159071.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159072,AML 6378,GSM159072,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,47 years,FAB M4,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159072/suppl/GSM159072.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159073,AML 6379,GSM159073,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,50 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159073/suppl/GSM159073.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159074,AML 6448,GSM159074,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,50 years,RAEB-t,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159074/suppl/GSM159074.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159075,AML 6714,GSM159075,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,47 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159075/suppl/GSM159075.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159076,AML 6883,GSM159076,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,42 years,FAB M4,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159076/suppl/GSM159076.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159077,AML 6884,GSM159077,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,19 years,FAB M4,cytogenetic intermediate,wild type,Other,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159077/suppl/GSM159077.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159078,AML 6885,GSM159078,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,42 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159078/suppl/GSM159078.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159079,AML 6887,GSM159079,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,41 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159079/suppl/GSM159079.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159080,AML 6888,GSM159080,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M5,cytogenetic poor,wild type,abn(3q),Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159080/suppl/GSM159080.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159081,AML 6889,GSM159081,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,36 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159081/suppl/GSM159081.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159082,AML 6890,GSM159082,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,,,,,,,,,,,,,,,,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159082/suppl/GSM159082.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,female,37 years,FAB M3,cytogenetic good,wild type,,Neg,Pos,Neg,Neg,Neg,Neg,neg,failure,,,
GSM159083,AML 6891,GSM159083,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,,,,,,,,,,,,,,,,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159083/suppl/GSM159083.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,male,56 years,FAB M4,cytogenetic good,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,idt(16),,,
GSM159084,AML 6892,GSM159084,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,21 years,FAB M1,cytogenetic good,wild type,idt(16),Neg,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159084/suppl/GSM159084.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159085,AML 6945,GSM159085,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,33 years,FAB M4,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159085/suppl/GSM159085.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159086,AML 6947,GSM159086,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,21 years,FAB M1,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159086/suppl/GSM159086.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159087,AML 6948,GSM159087,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,22 years,FAB M5,cytogenetic poor,wild type,-5/7(q),Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159087/suppl/GSM159087.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159088,AML 6949,GSM159088,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,33 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159088/suppl/GSM159088.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159089,AML 6952,GSM159089,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,52 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159089/suppl/GSM159089.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159090,AML 6953,GSM159090,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,55 years,FAB M6,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159090/suppl/GSM159090.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159091,AML 6955,GSM159091,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,31 years,FAB M2,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159091/suppl/GSM159091.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159092,AML 6974,GSM159092,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,32 years,FAB M6,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Pos,Neg,Neg,nd,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159092/suppl/GSM159092.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159093,AML 6975,GSM159093,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M4,cytogenetic intermediate,double mutant,-9q,Neg,Pos,Neg,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159093/suppl/GSM159093.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159094,AML 6976,GSM159094,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,31 years,FAB M0,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159094/suppl/GSM159094.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159095,AML 6977,GSM159095,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,33 years,FAB M5,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159095/suppl/GSM159095.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159096,AML 6979,GSM159096,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,56 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159096/suppl/GSM159096.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159097,AML 6980,GSM159097,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,17 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159097/suppl/GSM159097.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159098,AML 6981,GSM159098,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,17 years,FAB M5,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Pos,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159098/suppl/GSM159098.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159099,AML 6982,GSM159099,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,47 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159099/suppl/GSM159099.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159100,AML 7051,GSM159100,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,59 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159100/suppl/GSM159100.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159101,AML 7052,GSM159101,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,34 years,FAB M2,cytogenetic intermediate,wild type,Other,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159101/suppl/GSM159101.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159102,AML 7053,GSM159102,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,29 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159102/suppl/GSM159102.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159103,AML 7054,GSM159103,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,44 years,FAB M4,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159103/suppl/GSM159103.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159104,AML 7055,GSM159104,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,43 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159104/suppl/GSM159104.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159105,AML 7056,GSM159105,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,17 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159105/suppl/GSM159105.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159106,AML 7057,GSM159106,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,56 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159106/suppl/GSM159106.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159107,AML 7058,GSM159107,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,54 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159107/suppl/GSM159107.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159108,AML 7059,GSM159108,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,43 years,FAB M0,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159108/suppl/GSM159108.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159109,AML 7061,GSM159109,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,31 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,nd,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159109/suppl/GSM159109.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159110,AML 7062,GSM159110,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,53 years,FAB M2,cytogenetic good,wild type,t(8;21),Neg,Neg,Neg,Neg,Neg,Neg,nd,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159110/suppl/GSM159110.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159111,AML 7063,GSM159111,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,48 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159111/suppl/GSM159111.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159112,AML 7065,GSM159112,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,45 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159112/suppl/GSM159112.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159113,AML 7067,GSM159113,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,42 years,FAB M1,cytogenetic intermediate,wild type,,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159113/suppl/GSM159113.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159114,AML 7069,GSM159114,Public on Mar 12 2008,Jan 29 2007,Jul 28 2011,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,,,,,,,,,,,,,,,,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,"Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,,The CEL file for this Sample is not available.","MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,NONE,,"GSE6891,GSE14468",54675,,male,61 years,FAB M2,cytogenetic poor,wilde type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,-5/7(q),,,
GSM159115,AML 7070,GSM159115,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,39 years,FAB M4,cytogenetic intermediate,wild type,,Neg,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159115/suppl/GSM159115.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159116,AML 7071,GSM159116,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,50 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159116/suppl/GSM159116.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159117,AML 7072,GSM159117,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,60 years,FAB M4,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159117/suppl/GSM159117.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159118,AML 7073,GSM159118,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,37 years,FAB M4,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159118/suppl/GSM159118.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159119,AML 7074,GSM159119,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,45 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159119/suppl/GSM159119.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159120,AML 7075,GSM159120,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,55 years,FAB M4,cytogenetic intermediate,single mutant,Other,Neg,Neg,Pos,Neg,Neg,Neg,pos,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159120/suppl/GSM159120.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159121,AML 7076,GSM159121,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,40 years,FAB M0,cytogenetic poor,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159121/suppl/GSM159121.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159122,AML 7077,GSM159122,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,53 years,RAEB,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159122/suppl/GSM159122.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159123,AML 7078,GSM159123,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,55 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159123/suppl/GSM159123.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159124,AML 7079,GSM159124,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,28 years,FAB M5,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159124/suppl/GSM159124.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159125,AML 7119,GSM159125,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,57 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159125/suppl/GSM159125.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159126,AML 7120,GSM159126,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,51 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159126/suppl/GSM159126.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159127,AML 7121,GSM159127,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,49 years,FAB M2,unknown,wild type,failure,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159127/suppl/GSM159127.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159128,AML 7122,GSM159128,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,18 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159128/suppl/GSM159128.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159129,AML 7144,GSM159129,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,51 years,FAB M5,cytogenetic intermediate,wild type,,Pos,Neg,Neg,Pos,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159129/suppl/GSM159129.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159130,AML 7164,GSM159130,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,48 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159130/suppl/GSM159130.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159131,AML 7166,GSM159131,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,44 years,FAB M5,cytogenetic poor,wild type,,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159131/suppl/GSM159131.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159132,AML 7168,GSM159132,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,female,33 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159132/suppl/GSM159132.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159133,AML 7169,GSM159133,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,54 years,FAB M2,cytogenetic intermediate,wild type,,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159133/suppl/GSM159133.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159134,AML 7171,GSM159134,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,22 years,FAB unknown,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159134/suppl/GSM159134.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159135,AML 7180,GSM159135,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,38 years,FAB M1,cytogenetic intermediate,wild type,,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159135/suppl/GSM159135.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159136,AML 7186,GSM159136,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,40 years,FAB M2,unknown,wild type,failure,Pos,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159136/suppl/GSM159136.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159137,AML 7187,GSM159137,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,21 years,FAB M2,cytogenetic intermediate,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159137/suppl/GSM159137.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159138,AML 7188,GSM159138,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,51 years,FAB M5,unknown,wild type,failure,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159138/suppl/GSM159138.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159139,AML 7190,GSM159139,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,58 years,FAB M6,cytogenetic poor,wild type,,Neg,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159139/suppl/GSM159139.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159140,AML 7191,GSM159140,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,45 years,FAB M5,cytogenetic intermediate,wild type,,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159140/suppl/GSM159140.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159141,AML 7272,GSM159141,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,pos,male,48 years,FAB M2,cytogenetic poor,wild type,Other,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159141/suppl/GSM159141.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159142,AML 7273,GSM159142,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,22 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159142/suppl/GSM159142.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159143,AML 7274,GSM159143,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,37 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159143/suppl/GSM159143.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159144,AML 7312,GSM159144,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,33 years,RAEB,cytogenetic poor,wild type,MDS complex,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159144/suppl/GSM159144.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159145,AML 7408,GSM159145,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,pos,neg,male,55 years,FAB M1,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159145/suppl/GSM159145.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159146,AML 7409,GSM159146,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,56 years,FAB M0,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159146/suppl/GSM159146.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159147,AML 7410,GSM159147,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,57 years,FAB M3,cytogenetic good,wild type,t(15;17),Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159147/suppl/GSM159147.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159148,AML 7411,GSM159148,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159148/suppl/GSM159148.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159149,AML 7412,GSM159149,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,17 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159149/suppl/GSM159149.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159150,AML 7413,GSM159150,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,59 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159150/suppl/GSM159150.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159151,AML 7414,GSM159151,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,54 years,FAB M5,cytogenetic intermediate,wild type,NN,Pos,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159151/suppl/GSM159151.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159152,AML 7416,GSM159152,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,55 years,FAB M4,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159152/suppl/GSM159152.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159153,AML 7417,GSM159153,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,29 years,FAB M4,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159153/suppl/GSM159153.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159154,AML 7418,GSM159154,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,46 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159154/suppl/GSM159154.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159155,AML 7419,GSM159155,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,58 years,FAB M4,cytogenetic poor,wild type,Complex,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159155/suppl/GSM159155.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159156,AML 7420,GSM159156,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,56 years,FAB M1,cytogenetic intermediate,wild type,NN,Neg,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159156/suppl/GSM159156.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159157,AML 7421,GSM159157,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,46 years,FAB M2,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159157/suppl/GSM159157.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159158,AML 7423,GSM159158,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,40 years,FAB M0,cytogenetic intermediate,wild type,NN,Neg,Neg,Pos,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159158/suppl/GSM159158.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159159,AML 7479,GSM159159,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,56 years,FAB M0,cytogenetic intermediate,wild type,Other,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159159/suppl/GSM159159.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159160,AML 5360,GSM159160,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,29 years,FAB M1,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159160/suppl/GSM159160.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159161,AML 5361,GSM159161,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,28 years,FAB M2,cytogenetic poor,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159161/suppl/GSM159161.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159162,AML 6238,GSM159162,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,30 years,FAB M4,cytogenetic poor,wild type,11q23,Neg,Neg,Neg,Neg,Neg,Pos,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159162/suppl/GSM159162.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159163,AML 6240,GSM159163,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,female,55 years,FAB M2,cytogenetic poor,wild type,-5/7(q),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159163/suppl/GSM159163.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159164,AML 6241,GSM159164,Public on Mar 12 2008,Jan 29 2007,Aug 28 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,48 years,FAB M4,cytogenetic intermediate,wild type,NN,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159164/suppl/GSM159164.CEL.gz,Reanalyzed by: GSE119087,"GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159165,AML 6242,GSM159165,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,52 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159165/suppl/GSM159165.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159166,AML 6243,GSM159166,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,18 years,FAB M4,cytogenetic good,wild type,idt(16),Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159166/suppl/GSM159166.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159167,AML 6244,GSM159167,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,female,57 years,FAB M2,cytogenetic intermediate,wild type,+8,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159167/suppl/GSM159167.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159168,AML 6245,GSM159168,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,pos,male,55 years,FAB M2,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159168/suppl/GSM159168.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159169,AML 6359,GSM159169,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,53 years,RAEB-t,cytogenetic poor,wild type,MDS complex,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159169/suppl/GSM159169.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159170,AML 6361,GSM159170,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,60 years,RAEB-t,cytogenetic intermediate,wild type,NN,Neg,Neg,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159170/suppl/GSM159170.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM159171,AML 7320,GSM159171,Public on Mar 12 2008,Jan 29 2007,Nov 14 2018,RNA,1,"Blasts and mononuclear cells, AML patient",Homo sapiens,9606,Acute myeloid leukemia,blasts and mononuclear cells,neg,neg,male,34 years,FAB M5,cytogenetic intermediate,wild type,,Pos,Pos,Neg,Neg,Neg,Neg,neg,total RNA,Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.,biotin,Affymetrix protocol.,Affymetrix protocol.,Affymetrix protocol.,Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.,"MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.",GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159171/suppl/GSM159171.CEL.gz,"Reanalyzed by: GSE119087,Reanalyzed by: GSE122511","GSE6891,GSE14468",54675,,,,,,,,,,,,,,,,,,
GSM768679,AML 1448,GSM768679,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768679/suppl/GSM768679_1448.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768680,AML 2704,GSM768680,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768680/suppl/GSM768680_2704.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768681,AML 3329,GSM768681,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768681/suppl/GSM768681_3329.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768682,AML 3330,GSM768682,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768682/suppl/GSM768682_3330.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768683,AML 3331,GSM768683,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768683/suppl/GSM768683_3331.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768684,AML 3332,GSM768684,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768684/suppl/GSM768684_3332.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768685,AML 3485,GSM768685,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768685/suppl/GSM768685_3485.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768686,AML 3486,GSM768686,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768686/suppl/GSM768686_3486.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768687,AML 3487,GSM768687,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768687/suppl/GSM768687_3487.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768688,AML 3488,GSM768688,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768688/suppl/GSM768688_3488.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768689,AML 3489,GSM768689,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768689/suppl/GSM768689_3489.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768690,AML 3490,GSM768690,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768690/suppl/GSM768690_3490.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768691,AML 3491,GSM768691,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768691/suppl/GSM768691_3491.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768692,AML 3492,GSM768692,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768692/suppl/GSM768692_3492.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768693,AML 3493,GSM768693,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768693/suppl/GSM768693_3493.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768694,AML 4342,GSM768694,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768694/suppl/GSM768694_4342.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768695,AML 5287,GSM768695,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768695/suppl/GSM768695_5287.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768696,AML 5288,GSM768696,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768696/suppl/GSM768696_5288.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768697,AML 5289,GSM768697,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768697/suppl/GSM768697_5289.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768698,AML 5290,GSM768698,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768698/suppl/GSM768698_5290.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768699,AML 5291,GSM768699,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768699/suppl/GSM768699_5291.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768700,AML 5292,GSM768700,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768700/suppl/GSM768700_5292.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768701,AML 5348,GSM768701,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768701/suppl/GSM768701_5348.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768702,AML 5349,GSM768702,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768702/suppl/GSM768702_5349.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768703,AML 5350,GSM768703,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768703/suppl/GSM768703_5350.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768704,AML 5351,GSM768704,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768704/suppl/GSM768704_5351.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768705,AML 5352,GSM768705,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768705/suppl/GSM768705_5352.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768706,AML 5353,GSM768706,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768706/suppl/GSM768706_5353.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768707,AML 5354,GSM768707,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768707/suppl/GSM768707_5354.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768708,AML 5355,GSM768708,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768708/suppl/GSM768708_5355.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768709,AML 6356,GSM768709,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768709/suppl/GSM768709_6356.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768710,AML 6357,GSM768710,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768710/suppl/GSM768710_6357.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768711,AML 6449,GSM768711,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768711/suppl/GSM768711_6449.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768712,AML 6450,GSM768712,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768712/suppl/GSM768712_6450.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768713,AML 6451,GSM768713,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768713/suppl/GSM768713_6451.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768714,AML 6452,GSM768714,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768714/suppl/GSM768714_6452.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768715,AML 6453,GSM768715,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768715/suppl/GSM768715_6453.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768716,AML 6454,GSM768716,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768716/suppl/GSM768716_6454.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768717,AML 6455,GSM768717,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768717/suppl/GSM768717_6455.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768718,AML 6456,GSM768718,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768718/suppl/GSM768718_6456.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768719,AML 6457,GSM768719,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768719/suppl/GSM768719_6457.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768720,AML 6458,GSM768720,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768720/suppl/GSM768720_6458.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768721,AML 6459,GSM768721,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768721/suppl/GSM768721_6459.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768722,AML 6461,GSM768722,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768722/suppl/GSM768722_6461.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768723,AML 6462,GSM768723,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768723/suppl/GSM768723_6462.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768724,AML 6463,GSM768724,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768724/suppl/GSM768724_6463.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768725,AML 7066,GSM768725,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768725/suppl/GSM768725_7066.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768726,AML 7068,GSM768726,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768726/suppl/GSM768726_7068.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768727,AML 7084,GSM768727,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768727/suppl/GSM768727_7084.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768728,AML 7116,GSM768728,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768728/suppl/GSM768728_7116.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768729,AML 7117,GSM768729,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768729/suppl/GSM768729_7117.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768730,AML 7118,GSM768730,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768730/suppl/GSM768730_7118.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768731,AML 7129,GSM768731,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768731/suppl/GSM768731_7129.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768732,AML 7130,GSM768732,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768732/suppl/GSM768732_7130.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768733,AML 7132,GSM768733,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768733/suppl/GSM768733_7132.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768734,AML 7136,GSM768734,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768734/suppl/GSM768734_7136.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768735,AML 7146,GSM768735,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768735/suppl/GSM768735_7146.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768736,AML 7148,GSM768736,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768736/suppl/GSM768736_7148.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768737,AML 7161,GSM768737,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768737/suppl/GSM768737_7161.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768738,AML 7165,GSM768738,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768738/suppl/GSM768738_7165.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768739,AML 7167,GSM768739,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768739/suppl/GSM768739_7167.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768740,AML 7176,GSM768740,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768740/suppl/GSM768740_7176.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768741,AML 7179,GSM768741,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768741/suppl/GSM768741_7179.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768742,AML 7321,GSM768742,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768742/suppl/GSM768742_7321.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768743,AML 7322,GSM768743,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768743/suppl/GSM768743_7322.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768744,AML 7323,GSM768744,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768744/suppl/GSM768744_7323.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768745,AML 7324,GSM768745,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768745/suppl/GSM768745_7324.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768746,AML 7325,GSM768746,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768746/suppl/GSM768746_7325.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768747,AML 7326,GSM768747,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768747/suppl/GSM768747_7326.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768748,AML 7327,GSM768748,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768748/suppl/GSM768748_7327.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768749,AML 7328,GSM768749,Public on Jul 31 2011,Jul 28 2011,Jul 31 2011,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768749/suppl/GSM768749_7328.cel.gz,,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768750,AML 7404,GSM768750,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768750/suppl/GSM768750_7404.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768751,AML 7424,GSM768751,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768751/suppl/GSM768751_7424.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768752,AML 7425,GSM768752,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768752/suppl/GSM768752_7425.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768753,AML 7426,GSM768753,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768753/suppl/GSM768753_7426.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
GSM768754,AML 7427,GSM768754,Public on Jul 31 2011,Jul 28 2011,Nov 14 2018,RNA,1,mononuclear cells from bone marrow,Homo sapiens,9606,,,,,,,,,,,,,,,,,,total RNA,"The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols.",Biotin,"For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24  T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).","Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.",Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.,AML,The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default settings and targeted intensity values at 100. Intensity values were log2 transformed.,GPL570,"Roel,,Verhaak",rverhaak@mdanderson.org,Verhaak,Bioinformatics and Comp Bio,MD Anderson Cancer Center,1400 Pressler St,Houston,TX,77030,USA,http://odin.mdacc.tmc.edu/~rverhaak/,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM768nnn/GSM768754/suppl/GSM768754_7427.cel.gz,Reanalyzed by: GSE122511,GSE6891,54675,,,,,,,,,,,,,,,,mononuclear cells from bone marrow,Acute myeloid leukemia,Samples are from untreated patients (de novo AML)
